WO2022102740A1 - 好中球/リンパ球比低下剤 - Google Patents
好中球/リンパ球比低下剤 Download PDFInfo
- Publication number
- WO2022102740A1 WO2022102740A1 PCT/JP2021/041699 JP2021041699W WO2022102740A1 WO 2022102740 A1 WO2022102740 A1 WO 2022102740A1 JP 2021041699 W JP2021041699 W JP 2021041699W WO 2022102740 A1 WO2022102740 A1 WO 2022102740A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- curcumin
- neutrophil
- blood
- lymphocyte ratio
- water
- Prior art date
Links
- 230000003247 decreasing effect Effects 0.000 title abstract 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 103
- 235000012754 curcumin Nutrition 0.000 claims abstract description 67
- 229940109262 curcumin Drugs 0.000 claims abstract description 44
- 239000004148 curcumin Substances 0.000 claims abstract description 43
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 43
- 210000004369 blood Anatomy 0.000 claims abstract description 36
- 239000008280 blood Substances 0.000 claims abstract description 36
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 46
- 210000000440 neutrophil Anatomy 0.000 claims description 46
- 239000000126 substance Substances 0.000 claims description 31
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 19
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 claims description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 9
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 229940097043 glucuronic acid Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229940024606 amino acid Drugs 0.000 claims description 6
- 229940032330 sulfuric acid Drugs 0.000 claims description 6
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 claims description 5
- IGNHPXIJRJBNOR-XOAFEWEFSA-N (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[4-[(1E,3Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trienyl]-2-methoxyphenoxy]oxane-2-carboxylic acid Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)\C=C(/O)\C=C\C=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)=CC=2)=C1 IGNHPXIJRJBNOR-XOAFEWEFSA-N 0.000 claims description 5
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 claims description 5
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 claims description 5
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 claims description 5
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 claims description 5
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 claims description 5
- 229960003180 glutathione Drugs 0.000 claims description 5
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 abstract description 6
- -1 curcumin compound Chemical class 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 244000163122 Curcuma domestica Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 6
- 235000003373 curcuma longa Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 208000001528 Coronaviridae Infections Diseases 0.000 description 5
- 235000003392 Curcuma domestica Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 235000013976 turmeric Nutrition 0.000 description 5
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000008601 Polycythemia Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000002554 disease preventive effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002071 myeloproliferative effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 208000016583 Anus disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000001081 curcuma longa l. root oleoresin Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 235000013975 turmeric oleoresin Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates to a neutrophil / lymphocyte ratio lowering agent in blood.
- Leukocytes are immunocompetent cells involved in biological defense, and eliminate foreign substances such as bacteria and viruses that have invaded from outside the body, tumor cells, and cells that have finished their functions.
- white blood cells There are five types of white blood cells: monocytes, lymphocytes, neutrophils, basophils, and eosinophils.
- lymphocytes are divided into natural killer cells, T cells, and B cells, and have a function of attacking small foreign substances such as viruses and tumor cells in particular.
- neutrophils exhibit migratory properties against inflammatory cytokines, bacteria and fungi, gather in the inflamed area, phagocytose, sterilize and decompose foreign substances such as bacteria and fungi to protect the living body.
- neutrophils and lymphocytes have different roles, the number of lymphocytes does not change much, and the number of neutrophils increases due to bacterial infection, inflammation, cancer, and the like.
- Non-Patent Document 1 Non-Patent Document 1
- diabetes diabetes
- coronary artery disease or bacterial / viral infection
- COVID-19 new coronavirus infection
- COVID-19 new coronavirus infection
- Rotterdam study epidemiological survey of the general population aged 45 and over has shown that a high neutrophil lymphocyte ratio shortens lifespan.
- curcumin has pharmacological actions such as tumor formation inhibitory action, antioxidant action, anti-inflammatory action, cholesterol lowering action, antiallergic action (anti-IL-6 action, etc.), brain disease preventive action, and heart disease preventive and therapeutic action.
- Patent Document 1 which has been studied for use in pharmaceuticals, foods, cosmetics, etc.
- Non-Patent Document 3 Mazumar A. Et al. Report on the HIV inhibitory effect of curcumin.
- an object of the present invention is to provide a drug or food composition capable of lowering the neutrophil / lymphocyte ratio.
- the present inventor measured changes in the neutrophil / lymphocyte ratio by continuously administering a component confirmed to be highly safe to relatively old humans, and found that curcumins were found in the blood. We have found that it has the effect of strongly lowering the neutrophil / lymphocyte ratio, and completed the present invention.
- the present invention provides the following inventions [1] to [12].
- [1] A neutrophil / lymphocyte ratio lowering agent in blood containing curcumin as an active ingredient.
- composition according to the above [7], wherein the curcumins are one or more selected from curcumin, curcumin derivatives, and conjugates thereof with a water-soluble substance.
- curcumin derivative is at least one selected from bisdemethoxycurcumin, demethoxycurcumin and tetrahydrocurcumin.
- water-soluble substance is at least one selected from glucuronic acid, sulfuric acid, glutathione and amino acids.
- the water-soluble substance is at least one selected from glucuronic acid and sulfuric acid.
- curcumins used to reduce the neutrophil / lymphocyte ratio in blood.
- curcumin is one or more selected from curcumin, a curcumin derivative, and a conjugate thereof with a water-soluble substance.
- curcumins are one or more selected from curcumin, curcumin derivatives, and conjugates thereof with a water-soluble substance.
- [17] A method for lowering the neutrophil / lymphocyte ratio in blood, which comprises administering an effective amount of curcumin.
- the curcumins are one or more selected from curcumin, curcumin derivatives, and conjugates thereof with a water-soluble substance.
- curcumins lowers the neutrophil / lymphocyte ratio in the blood. Therefore, patients with high neutrophil / lymphocyte ratios can improve the prognosis of the disease they are suffering from.
- diseases include allergic diseases such as asthma and atopic dermatitis, autoimmune diseases such as rheumatoid arthritis, arteriosclerosis, cardiovascular disease, heart failure, kidney disease, Alzheimer's disease, as well as septicemia and pneumonia.
- Severe infections rheumatic fever, malignant tumors, chronic myeloproliferative leukemia, true erythrocytosis, essential thrombocytosis, myelodystrophy, and severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and COVID Examples include viral infections such as -19 (SARS-Cov-2), which can improve the prognosis of these diseases.
- the active ingredient of the neutrophil / lymphocyte ratio improving agent in blood and the food composition for improving the neutrophil / lymphocyte ratio in blood of the present invention is curcumin.
- the curcumins include one or more selected from curcumin, curcumin derivatives, and conjugates thereof with a water-soluble substance.
- Curcumin is the main component of curcuminoids contained in turmeric pigments, and is a compound represented by the following structural formula (1).
- curcumin Derivatives of curcumin include bisdemethoxycurcumin, demethoxycurcumin and tetrahydrocurcumin.
- curcumin chemically synthesized curcumin may be used, or curcumin distributed as a turmeric pigment may be used.
- curcumin turmeric powder obtained by powdering dried rhizome of Curcuma longa LINNE, and the turmeric powder using an appropriate solvent (for example, ethanol, fat, propylene glycol, hexane, acetone, etc.) are used.
- an appropriate solvent for example, ethanol, fat, propylene glycol, hexane, acetone, etc.
- examples thereof include crude curcumin or oleoresin (turmeric oleoresin) obtained by extraction, and purified curcumin.
- curcumin includes both keto type and enol type which are tautomers.
- Examples of the water-soluble substance in the conjugate of the curcumin or curcumin derivative of the present invention and the water-soluble substance include one or more selected from glucuronic acid, sulfuric acid, glutathion and amino acids.
- Examples of amino acids include amino acids existing in the living body, for example, essential amino acids.
- a conjugate of curcumin and a water-soluble substance can maintain a high blood concentration of free curcumin. As a result, the pharmacological action of curcumin can be sufficiently obtained.
- the conjugate of curcumin and a water-soluble substance is preferable because it is a metabolite of curcumin in vivo and has very high safety.
- the conjugation form (binding form) of curcumin and the water-soluble substance is, for example, the form of the formula (2).
- R 1 and R 2 are residue of the water-soluble substance, and the remainder is a hydrogen atom.
- R 1 and R 2 are preferably a glucuronic acid residue or a sulfuric acid residue, and the remainder is preferably a hydrogen atom.
- curcumin monoglucuronide in which R 1 is a glucuronic acid residue and R 2 is a hydrogen atom, is more preferable.
- the conjugate of curcumin and a water-soluble substance can be produced by the method described in WO2018 / 003857.
- the curcumins have the effect of strongly lowering the neutrophil / lymphocyte ratio in blood, as shown in Examples below. Therefore, the neutrophil / lymphocyte ratio lowering agent in blood and the food composition for lowering neutrophil / lymphocyte ratio in blood containing the curcumins have a high neutrophil / lymphocyte ratio in blood. It has the effect of improving the prognosis of the disease.
- diseases that are likely to improve the prognosis include allergic diseases such as asthma and atopic dermatitis, autoimmune diseases such as rheumatoid arthritis, arteriosclerosis, cardiovascular disease, heart failure, kidney disease, and Alzheimer's disease.
- SARS severe acute respiratory syndrome
- MERS Middle East Respiratory Syndrome
- SARS-Cov-2 COVID-19
- the content of curcumin in the agent and composition of the present invention cannot be unconditionally determined, but is preferably 1 to 100% by mass, more preferably 5 to 100% by mass, and 10 to 100% by mass, for example. More preferred.
- the administration route of the neutrophil / lymphocyte ratio lowering agent in the blood of the present invention can be selected from systemic administration and local administration, or oral route and parenteral route, depending on the disease, symptoms and the like.
- Oral administration in the form of suitable dosage forms such as tablets, rounds, capsules, granules, powders, liquids, etc., or injections (eg, intravenous injection, intramuscular injection, etc.), depending on the administration method and route.
- Parenteral administration in the form of suppositories, transdermal agents, nasal agents, inhalants and the like can be selected.
- the pharmaceutical product for oral administration according to the present invention may be a solid pharmaceutical product such as tablets, capsules, powders and granules.
- a preparation is produced according to a conventional method by mixing one or more active substances with an inert excipient, lubricant, disintegrant, solubilizing agent and the like.
- Excipients can be, for example, lactose, cellulose, mannitol, glucose.
- the lubricant can be, for example, magnesium stearate.
- the disintegrant can be, for example, sodium carboxymethyl starch. Tablets or pills may be coated with a sugar coating or a gastric or enteric coating, if desired.
- the therapeutic agent for oral administration may be a liquid preparation such as a pharmacologically acceptable extract, emulsion, liquid, suspension, syrup, alcohol, or elixir.
- a liquid preparation such as a pharmacologically acceptable extract, emulsion, liquid, suspension, syrup, alcohol, or elixir.
- Such formulations contain commonly used inert solvents (eg, purified water, ethanol, etc.) and further include solubilizers, wetting agents, suspending agents, sweeteners, citrates, fragrances, etc. It may contain a buffer (eg, sodium citrate, etc.), a stabilizer or a preservative.
- Therapeutic agents for parenteral administration include sterile aqueous or non-aqueous liquids, suspensions, or injections such as emulsions, ointments and lotions, sublingual agents for oral administration, oral patches, and nasal administration.
- an injection it can be administered by injection into a joint, subcutaneous, intracutaneous, intramuscular, etc., in addition to the usual intravenous administration and intraarterial administration.
- the aqueous solvent for the injectable solution can be, for example, distilled water or saline.
- the non-aqueous solvent for the injectable solution can be, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, or polysorbate 80 (diplinary name).
- Such formulations also include tonicity agents (eg, sodium chloride, glucose, etc.), preservatives, wetting agents, emulsifiers, dispersants, stabilizers, pH adjusters (eg, sodium citrate, sodium acetate, phosphorus). It may contain a buffer (eg, sodium acetate, etc.), a local anesthetic (eg, prokine hydrochloride, lidocaine hydrochloride, etc.) or a solubilizing agent.
- tonicity agents eg, sodium chloride, glucose, etc.
- preservatives eg, wetting agents, emulsifiers, dispersants, stabilizers
- pH adjusters eg, sodium citrate, sodium acetate, phosphorus
- It may contain
- formulations can be sterilized, for example, by filtration through a bacterial retention filter, formulation of a fungicide, or irradiation.
- composition obtained by dissolving or suspending a sterile solid composition in sterile water or an injection solvent before use can also be used as these preparations.
- These preparations can be produced by a known method usually used in the preparation process.
- Examples of the form of the food composition for lowering the neutrophil / lymphocyte ratio in blood of the present invention include tablets, pills, capsules, granules, powders, liquids (including drinks) and the like. These forms can be produced in the same manner as the above-mentioned oral administration preparation.
- the dose of the neutrophil / lymphocyte ratio lowering agent in blood or the food composition for lowering neutrophil / lymphocyte ratio in blood of the present invention is not particularly limited, but is 10 mg to 10 g per day for adults as curcumins. Is preferable, and 30 mg to 10 g is more preferable.
- Example 1 Twenty men and women over the age of 60 were given curcumin-containing capsules (containing 90 mg of curcumin per capsule) twice daily in the morning and evening for 4 weeks (daily dose of 180 mg). Venous blood was collected at the start and end of administration, and the neutrophil / lymphocyte ratio was measured. As a result, in the non-parametric test (Wilcoxon signed rank test), the neutrophil / lymphocyte ratio at the start of administration was 1.7 (1.3, 2.1), whereas it was favorable at the end of administration. The neutrophil / lymphocyte ratio is 1.4 (1.2, 1.7). The risk rate was 0.02%, which was significantly reduced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
このうち、リンパ球は、ナチュラルキラー細胞、T細胞、B細胞に分けられ、特にウイルスなどの小さな異物や腫瘍細胞に対して攻撃する機能を有している。一方、好中球は、炎症性サイトカインや細菌、真菌類に対して遊走性を示し、炎症部に集合し、細菌、真菌等の異物の貪食、殺菌、分解を行い、生体を防御する。
このように、好中球とリンパ球とは、それぞれ役割が異なっており、リンパ球の数はあまり変化せず、好中球の数は細菌感染症、炎症、癌などで増加する。
またMazumdar A.らは、クルクミンのHIV阻害作用に関して報告している(非特許文献3)。
従って、本発明の課題は、好中球/リンパ球比を低下させることができる薬剤又は食品組成物を提供することにある。
[1]クルクミン類を有効成分とする、血液中の好中球/リンパ球比低下剤。
[2]クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である上記[1]記載の血液中の好中球/リンパ球比低下剤。
[3]前記クルクミン誘導体が、ビスデメトキシクルクミン、デメトキシクルクミン及びテトラヒドロクルクミンから選ばれる1種以上である上記[2]記載の血液中の好中球/リンパ球比低下剤。
[4]前記水溶性物質が、グルクロン酸、硫酸、グルタチオン及びアミノ酸から選ばれる1種以上である上記[2]記載の血液中の好中球/リンパ球比低下剤。
[5]前記水溶性物質が、グルクロン酸及び硫酸から選ばれる1種以上である上記[2]記載の血液中の好中球/リンパ球比低下剤。
[6]前記クルクミン類がクルクミンモノグルクロニドである上記[1]記載の血液中の好中球/リンパ球比低下剤。
[7]クルクミン類を含有する、血液中の好中球/リンパ球比低下用食品組成物。
[8]クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である上記[7]記載の組成物。
[9]前記クルクミン誘導体が、ビスデメトキシクルクミン、デメトキシクルクミン及びテトラヒドロクルクミンから選ばれる1種以上である上記[8]記載の組成物。
[10]前記水溶性物質が、グルクロン酸、硫酸、グルタチオン及びアミノ酸から選ばれる1種以上である上記[8]記載の組成物。
[11]前記水溶性物質が、グルクロン酸及び硫酸から選ばれる1種以上である上記[8]記載の組成物。
[12]前記クルクミン類がクルクミンモノグルクロニドである上記[7]記載の組成物。
[13]血液中の好中球/リンパ球比を低下させるために用いるクルクミン類。
[14]クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である上記[13]記載のクルクミン類。
[15]血液中の好中球/リンパ球比低下剤を製造するための、クルクミン類の使用。
[16]クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である上記[15]記載の使用。
[17]クルクミン類の有効量を投与することを特徴とする、血液中の好中球/リンパ球比の低下方法。
[18]クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である上記[17]記載の方法。
当該クルクミン類としては、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上が挙げられる。
本発明においてクルクミンは、化学合成されたクルクミンを用いてもよいし、ウコン色素として流通しているものを用いてもよい。ウコン色素としては、ショウガ科ウコン(Curcuma longa LINNE)の根茎の乾燥物を粉末にしたウコン末、該ウコン末を適当な溶媒(例えば、エタノール、油脂、プロピレングリコール、ヘキサン、アセトンなど)を用いて抽出して得られる粗製クルクミン或いはオレオレジン(ターメリックオレオレジン)、及び精製したクルクミンを挙げることができる。
なお、クルクミンには、互変異性体であるケト型及びエノール型のいずれも含まれる。
例えばクルクミンと水溶性物質との抱合体は、遊離型クルクミンの血中濃度を高い値で維持することができる。これにより、クルクミンが有する薬理作用が十分に得られる。またクルクミンと水溶性物質との抱合体はクルクミンの生体内代謝産物であることから、安全性が非常に高いので好ましい。
クルクミンと前記水溶性物質との結合モル比は、クルクミン:水溶性物質=1:1~1:3であるのが好ましく、1:1~1:2がより好ましく、1:1がさらに好ましい。
クルクミンと水溶性物質との抱合体は、WO2018/003857号公報記載の方法によって製造することができる。
ここで、予後が改善される可能性の高い疾患としては、ぜんそくやアトピー性皮膚炎などのアレルギー性疾患、関節リウマチなどの自己免疫疾患、動脈硬化、心血管疾患、心不全、腎臓病、アルツハイマー病などのほか、敗血症、肺炎などの重度感染症、リウマチ熱、悪性腫瘍、慢性骨髄増殖性白血病、真性赤血球増加症、本態性血小板血症、骨髄繊維症、また重症急性呼吸器症候群(SARS)、中東呼吸器症候群(MERS)及びCOVID-19(SARS-Cov-2)等のウイルス感染症などが挙げられる。
また、クルクミン類は、すでに機能性食品として広く用いられており、安全性が高いことは確認されている。
滑沢剤は、例えば、ステアリン酸マグネシウムであり得る。崩壊剤は、例えば、カルボキシメチルスターチナトリウムであり得る。錠剤または丸剤は、必要により糖衣または胃溶性若しくは腸溶性コーティング剤で被膜してもよい。
注射剤の場合、通常の静脈内投与、動脈内投与の他、関節内、皮下、皮内、筋肉内等への注射により投与できる。注射剤用の水性の溶剤は、例えば、蒸留水または生理食塩水であり得る。注射剤用の非水性の溶剤は、例えば、プロピレングリコール、ポリエチレングリコール、オリーブ油のような植物油、エタノールのようなアルコール類、またはポリソルベート80(局方名)であり得る。このような製剤は、さらに等張化剤(例えば、塩化ナトリウム、ブドウ糖等)、防腐剤、湿潤剤、乳化剤、分散剤、安定化剤、pH調節剤(例えば、クエン酸ナトリウム、酢酸ナトリウム、リン酸ナトリウム等)、緩衝剤、局所麻酔剤(例えば、塩酸プロカイン、塩酸リドカイン等)または溶解補助剤を含有してもよい。
これらの製剤は、例えば、バクテリア保留フィルターによる濾過、殺菌剤の配合、又は放射線照射によって無菌化され得る。また、無菌の固体組成物を使用前に無菌の水又は注射用溶媒に溶解または懸濁して得られた組成物をこれらの製剤として使用することもできる。これらの製剤は、製剤工程において通常用いられる公知の方法により製造することができる。
60歳以上の男女20名に、クルクミン含有カプセル(1カプセル当たりクルクミンとして90mg含有)を、朝、夕1日2回ずつ4週間服用させた(1日投与量180mg)。投与開始時及び投与終了時に静脈血を採取し、好中球/リンパ球比を測定した。
その結果、ノンパラメトリック検定(Wilcoxon符号順位検定)で、投与開始時の好中球/リンパ球比が1.7(1.3、2.1)であったのに対し、投与終了時の好中球/リンパ球比が1.4(1.2、1.7)であり。危険率0.02%で有意に低下した。
Claims (18)
- クルクミン類を有効成分とする、血液中の好中球/リンパ球比低下剤。
- クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である請求項1記載の血液中の好中球/リンパ球比低下剤。
- 前記クルクミン誘導体が、ビスデメトキシクルクミン、デメトキシクルクミン及びテトラヒドロクルクミンから選ばれる1種以上である請求項2記載の血液中の好中球/リンパ球比低下剤。
- 前記水溶性物質が、グルクロン酸、硫酸、グルタチオン及びアミノ酸から選ばれる1種以上である請求項2記載の血液中の好中球/リンパ球比低下剤。
- 前記水溶性物質が、グルクロン酸及び硫酸から選ばれる1種以上である請求項2記載の血液中の好中球/リンパ球比低下剤。
- 前記クルクミン類がクルクミンモノグルクロニドである請求項1記載の血液中の好中球/リンパ球比低下剤。
- クルクミン類を含有する、血液中の好中球/リンパ球比低下用食品組成物。
- クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である請求項7記載の組成物。
- 前記クルクミン誘導体が、ビスデメトキシクルクミン、デメトキシクルクミン及びテトラヒドロクルクミンから選ばれる1種以上である請求項8記載の組成物。
- 前記水溶性物質が、グルクロン酸、硫酸、グルタチオン及びアミノ酸から選ばれる1種以上である請求項8記載の組成物。
- 前記水溶性物質が、グルクロン酸及び硫酸から選ばれる1種以上である請求項8記載の組成物。
- 前記クルクミン類がクルクミンモノグルクロニドである請求項7記載の組成物。
- 血液中の好中球/リンパ球比を低下させるために用いるクルクミン類。
- クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である請求項13記載のクルクミン類。
- 血液中の好中球/リンパ球比低下剤を製造するための、クルクミン類の使用。
- クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である請求項15記載の使用。
- クルクミン類の有効量を投与することを特徴とする、血液中の好中球/リンパ球比の低下方法。
- クルクミン類が、クルクミン、クルクミン誘導体、及びそれらと水溶性物質との抱合体から選ばれる1種以上である請求項17記載の方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022562198A JPWO2022102740A1 (ja) | 2020-11-12 | 2021-11-12 | |
US18/252,553 US20240000723A1 (en) | 2020-11-12 | 2021-11-12 | Neutrophil-to-lymphocyte ratio decreasing agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020188812 | 2020-11-12 | ||
JP2020-188812 | 2020-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022102740A1 true WO2022102740A1 (ja) | 2022-05-19 |
Family
ID=81602369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/041699 WO2022102740A1 (ja) | 2020-11-12 | 2021-11-12 | 好中球/リンパ球比低下剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240000723A1 (ja) |
JP (1) | JPWO2022102740A1 (ja) |
WO (1) | WO2022102740A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012510466A (ja) * | 2008-12-01 | 2012-05-10 | ライラ ファーマシューティカルズ ピーブイティ.エルティディ. | 炎症、皮膚異常及び粘膜異常並びに他の皮膚疾病及び粘膜疾病の治療のための局部用製剤 |
WO2018003857A1 (ja) * | 2016-06-29 | 2018-01-04 | 株式会社セラバイオファーマ | 非経口投与用医薬組成物 |
US20200046651A1 (en) * | 2018-08-10 | 2020-02-13 | Metagenics, Inc. | Method of treating inflammatory bowel disease |
JP2020026434A (ja) * | 2018-08-10 | 2020-02-20 | 株式会社セラバイオファーマ | 癌治療剤 |
-
2021
- 2021-11-12 WO PCT/JP2021/041699 patent/WO2022102740A1/ja active Application Filing
- 2021-11-12 US US18/252,553 patent/US20240000723A1/en active Pending
- 2021-11-12 JP JP2022562198A patent/JPWO2022102740A1/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012510466A (ja) * | 2008-12-01 | 2012-05-10 | ライラ ファーマシューティカルズ ピーブイティ.エルティディ. | 炎症、皮膚異常及び粘膜異常並びに他の皮膚疾病及び粘膜疾病の治療のための局部用製剤 |
WO2018003857A1 (ja) * | 2016-06-29 | 2018-01-04 | 株式会社セラバイオファーマ | 非経口投与用医薬組成物 |
US20200046651A1 (en) * | 2018-08-10 | 2020-02-13 | Metagenics, Inc. | Method of treating inflammatory bowel disease |
JP2020026434A (ja) * | 2018-08-10 | 2020-02-20 | 株式会社セラバイオファーマ | 癌治療剤 |
Non-Patent Citations (3)
Title |
---|
ATSUHIRO KISHIMOTO , ATSUSHI IMAIZUMI , HIROMICHI WADA , HAJIME YAMAKAGE , NORIKO SATOH-ASAHARA , TADASHI HASHIMOTO , KOJI H: "Newly Developed Highly Bioavailable Curcumin Formulation, curcuRouge TM , Reduces Neutrophil / Lymphocyte Ratio in the Elderly: A Double-Blind, Placebo-Controlled Clinical Trial", JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, vol. 67, no. 4, 31 August 2021 (2021-08-31), pages 249 - 252, XP055929370, ISSN: 0301-4800, DOI: 10.3177/jnsv.67.249 * |
RYAN JENNIFER J, HANES DOUGLAS A, BRADLEY RYAN D, CONTRACTOR NIKHAT: "Effect of a Nutrition Support Formula in Adults With Inflammatory Bowel Disease: A Pilot Study", GLOBAL ADVANCES IN HEALTH AND MEDICINE, vol. 8, 1 January 2019 (2019-01-01), pages 1 - 8, XP055929362, ISSN: 2164-9561, DOI: 10.1177/2164956119867251 * |
SUNAGAWA YOICHI; MIYAZAKI YUSUKE; FUNAMOTO MASAFUMI; SHIMIZU KANA; SHIMIZU SATOSHI; NURMILA SARI; KATANASAKA YASUFUMI; ITO MASASHI: "A novel amorphous preparation improved curcumin bioavailability in healthy volunteers: A single-dose, double-blind, two-way crossover study", JOURNAL OF FUNCTIONAL FOODS, vol. 81, 7 April 2021 (2021-04-07), NL , XP086572436, ISSN: 1756-4646, DOI: 10.1016/j.jff.2021.104443 * |
Also Published As
Publication number | Publication date |
---|---|
US20240000723A1 (en) | 2024-01-04 |
JPWO2022102740A1 (ja) | 2022-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190060253A1 (en) | Formulation of Curcumin with Enhanced Bioavailability of Curcumin and method of preparation and treatment thereof | |
US10159654B2 (en) | Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof | |
JP2017527614A (ja) | 重水素化又は非重水素化分子及び医薬製剤 | |
ES2657364T3 (es) | Formulación de curcumina con una biodisponibilidad mejorada de curcumina y método de preparación y tratamiento de la misma | |
JP6931853B2 (ja) | 非経口投与用医薬組成物 | |
JPH02202817A (ja) | ビス(3,5―ジー第三ブチル―4―ヒドロキシフェニルチオ)メタンの血液コレステロール低下及び抗アテローム性動脈硬化症剤としての用途 | |
JP6803898B2 (ja) | オメガ−3脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ | |
JP3714426B2 (ja) | フコイダンオリゴ糖組成物含有癌転移抑制剤 | |
EP0395441A2 (en) | Treating agent for osteoarthritis | |
US20170202785A1 (en) | Formulation of Curcumin with Enhanced Bioavailability of Curcumin and method of preparation and treatment thereof | |
TWI564291B (zh) | 一氧化氮生成調節劑 | |
JP2020026434A (ja) | 癌治療剤 | |
EP4122495A1 (en) | Treatment or prevention method for chronic heart failure | |
MXPA04011794A (es) | Composiciones para uso terapeutico que comprenden una vitamina, una sal de metal e insulina o una hormona de crecimiento. | |
WO2022102740A1 (ja) | 好中球/リンパ球比低下剤 | |
WO2021256547A1 (ja) | SARS-CoV-2感染症の治療、予防または緩和用組成物 | |
JP2012051830A (ja) | 胃粘膜保護剤 | |
EP0679394B1 (en) | Menatetronome derivative as antiarteriosclerotic agent | |
JP3243879B2 (ja) | 抗高脂血症剤 | |
JP3879938B2 (ja) | 抗炎症剤 | |
JP3860849B2 (ja) | 抗動脈硬化治療剤 | |
WO2021201264A1 (ja) | 変形性関節症の治療、予防又は緩和のための非経口投与用医薬組成物 | |
WO2022052055A1 (zh) | 一种包含安卓幸醇的组合物用于制备抑制肝癌细胞或肝癌干细胞生长的药物的用途 | |
TW202210073A (zh) | 一種包含安卓幸醇之組合物用於製備抑制肝癌細胞或肝癌幹細胞生長之藥物的用途 | |
Bahramsoltani et al. | Turmeric and Inflammatory Diseases: An Overview of Clinical Evidence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21891985 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022562198 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18252553 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21891985 Country of ref document: EP Kind code of ref document: A1 |